Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of DMYD-B.ST is 1.40 and suggests 39.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to